Company news
Swedish Orphan Biovitrum Ab (OMXSTO:SOBI) news
Every Swedish Orphan Biovitrum Ab press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Swedish Orphan Biovitrum : Sobi and Innate announce partnership is now effective following completion of closing conditions
September 16, 2026
Sobi and Innate announce partnership is now effective following completion of closing conditions
September 15, 2026
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
September 9, 2026
Sobi has completed an issue of class C shares
August 31, 2026
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
August 10, 2026
Guido Oelkers to step down as CEO of Sobi in the beginning of 2027
August 3, 2026
Sobi Q2 2026 report: Significant growth with important pipeline progress
July 16, 2026
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under an incentive programme
July 15, 2026
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
July 9, 2026
Sobi to showcase new data across haemophilia portfolio at ISTH 2026
June 30, 2026
Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
June 26, 2026
Sobi to present new clinical and real-world data at EHA 2026 in Stockholm
June 11, 2026
Sobi to present new data on pegcetacoplan at ERA 2026
June 1, 2026
Swedish Orphan Biovitrum : Sobi to present new data on pegcetacoplan at ERA 2026
June 1, 2026
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
May 26, 2026
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
May 21, 2026
Bulletin from Sobi's Annual General Meeting (AGM)
May 6, 2026
Sobi Q1 2026 report: Strong execution and pipeline momentum
April 28, 2026
Invitation: Sobi's Q1 2026 report
April 14, 2026
Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
April 9, 2026
Sobi publishes Annual and Sustainability Report for 2025
March 31, 2026
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
March 30, 2026
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
March 27, 2026
Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM
March 18, 2026
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030
February 18, 2026
Sobi to host a Capital Markets Day on 18 February 2026
February 11, 2026
Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
February 9, 2026
Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress
February 5, 2026
Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026
February 3, 2026
Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
January 16, 2026
Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook
January 15, 2026
Invitation: Sobi's Q4 and FY 2025 report
January 14, 2026
Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data
January 7, 2026
Save the Date: Sobi to host a Capital Markets Day on 18 February 2026
December 18, 2025
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
December 15, 2025
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
December 15, 2025
Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
December 12, 2025
Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
December 5, 2025
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN
December 4, 2025
Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
November 8, 2025
Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
November 5, 2025
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
October 25, 2025
Sobi showcases new data across rare inflammatory conditions at ACR 2025
October 24, 2025
Change in the Sobi Board of Directors
October 21, 2025
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
October 20, 2025
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
October 19, 2025
Invitation: Sobi's Q3 2025 report
October 8, 2025
Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments
October 2, 2025
New number of shares and votes in Sobi
September 30, 2025
Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
September 19, 2025